Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib combinations in mCRPC
NCT04087174Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by AstraZeneca. Primary endpoints: Dose Limiting Toxicity and Number of patients with adverse events up to 1.5 years. Started Aug 2019; status: completed.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04087174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087174.